O&G SAQs · Gynaecological health — premature ovarian insufficiency
Premature ovarian insufficiency — structured SAQ (15 marks)
FRANZCOG-format structured SAQ on premature ovarian insufficiency: the ESHRE 2024 diagnostic definition, the cause-finding workup (karyotype, FMR1, 21-hydroxylase antibody), HRT to age 51 as physiologic replacement, and honest fertility counselling. Per-sub-part marking rubric included.
On this page & tools
Target exams
How this SAQ is marked
Marks come from the verbatim ESHRE 2024 definition, the cause-finding workup (karyotype, FMR1 premutation, 21-hydroxylase antibody), the duration and rationale of HRT in POI, and honest fertility counselling. Write in short labelled points. [1]
Reveal model answer and mark scheme
(a) Definition and confirmation (3 marks)
- Definition (ESHRE 2024): premature ovarian insufficiency is loss of ovarian activity before age 40, characterised by menstrual disturbance (amenorrhoea or oligomenorrhoea) plus two serum FSH levels over 25 IU/L taken at least 4 weeks apart.
- Confirmation: exclude pregnancy first (done — negative), then repeat the FSH at least 4 weeks later — never diagnose on a single test, because POI fluctuates.
- Do NOT use anti-Mullerian hormone to diagnose POI.
(b) Cause-finding workup (4 marks)
- Karyotype — to identify 45,X mosaicism (Turner) and other X-chromosome abnormalities; the most common chromosomal cause.
- FMR1 premutation screen (CGG repeat, 55 to 200) — fragile X-associated POI (FXPOI).
- 21-hydroxylase antibodies (plus TSH and anti-thyroid antibodies) — to screen for coexisting Addison disease; an undiagnosed adrenal insufficiency can cause a fatal adrenal crisis. This is the must-not-miss.
- DEXA for bone density at diagnosis (low BMD is common — about 58% in the Bachelot cohort) and a cardiovascular risk assessment.
(c) Hormone therapy (5 marks)
- Offer HRT or a combined hormonal contraceptive (NICE NG23 1.7.6), unless contraindicated. HRT is generally preferred for long-term use (better blood-pressure profile, bone-protective); the COC is acceptable and contraceptive.
- Regimen: oestrogen plus a progestogen (she has a uterus); micronised progesterone is the modern progestogen of choice. Tibolone is an alternative.
- Duration: continue until at least the average age of natural menopause (around 51), unless contraindicated. Premature stopping is the common error.
- Rationale: this is physiologic replacement of hormones her ovaries are not making — NOT menopausal HRT. The baseline risk of breast cancer and cardiovascular disease is very low in women under 40, so the benefits outweigh the risks.
- The WHI risk numbers do NOT apply to her — they were for women with a mean age of 63 started years past menopause. Withholding HRT in POI is the error.
(d) Fertility counselling (3 marks)
- Spontaneous pregnancy is possible but uncommon (around 5 to 10% in some series) — POI fluctuates. Do not over-promise.
- Donor-oocyte IVF is the most realistic fertility option, with good success rates per cycle.
- Do not offer post-diagnosis oocyte freezing — the diagnosis means the reserve is already depleted. Fertility preservation (oocyte or embryo cryopreservation) must happen BEFORE gonadotoxic therapy, not after.
You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Obstetrics & Gynaecology fellowship atlas.
References4Show ledgerHide ledger
- [1]Panay N, Anderson RA, Bennie A, et al. Evidence-based guideline: premature ovarian insufficiency. Hum Reprod Open, 2024.PMID 39660328
- [2]Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod, 2016.PMID 27008889
- [3]Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric, 2020.PMID 32896176
- [4]Bachelot A, Rouxel A, Massin N, et al. Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. Eur J Endocrinol, 2009.PMID 19411303